Pharmaceutical

Botulinum battle heats up with FDA approving Daxxify for cervical dystonia

Daxxify becomes the latest botulinum toxin to make the jump from aesthetics to therapeutics.

Aug 14, 2023 - 20:00
Botulinum battle heats up with FDA approving Daxxify for cervical dystonia
Daxxify becomes the latest botulinum toxin to make the jump from aesthetics to therapeutics.
Read the original article

Tags:

Previous Article

STAT+: Pharma budget tightening trickles down to Doximity

Next Article

LifeArc invests nearly $10m in Crick Institute’s Africa Scheme

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Alvotech and Dr Reddy’s partner to commercialise AVT03

Alvotech and Dr Reddy’s partner to commercialise AVT03

May 23, 2024

CymaBay seeks FDA approval for primary biliary cholangitis therapy

CymaBay seeks FDA approval for primary biliary cholangi...

Dec 18, 2023

STAT+: Moderna CEO made $398 million in 2022, but still pledges to give most to charity

STAT+: Moderna CEO made $398 million in 2022, but still...

Mar 19, 2023